Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Baricitinib, Imatinib or Supportive Treatment in Patients With SARS Cov2 Pneumonia

Next Previous
Trial Profile

Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Baricitinib, Imatinib or Supportive Treatment in Patients With SARS Cov2 Pneumonia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary) ; Imatinib (Primary) ; Lopinavir/ritonavir (Primary)
  • Indications COVID-19 pneumonia
  • Focus Biomarker; Therapeutic Use
  • Acronyms Covid19COVINIB

Most Recent Events

  • 22 Sep 2023 Status changed from active, no longer recruiting to completed.
  • 02 Aug 2021 Status changed from recruiting to active, no longer recruiting.
  • 09 Feb 2021 Planned End Date changed from 1 May 2021 to 1 Sep 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top